



RECEIVED

MAY 29 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant(s): Paszty *et al.*

Serial No.: 09/818,954

Group Art Unit No.: 1647

Filed: March 27, 2001

Examiner: L. Spector, Ph.D.

For: BETA-LIKE GLYCOPROTEIN HORMONE
POLYPEPTIDE AND HETERODIMER

Docket No.: A-676B

DECLARATION OF CHRISTOPHER J. R. PASZTY, PH.D. UNDER 37 CFR 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Chris Paszty, hereby declare as follows:

1. I have been employed since February, 1998 by Amgen Inc.
2. I am a co-inventor on U.S. Patent Application Serial No. 09/818,954.
3. U.S. Patent Application Serial No. 09/818,954 makes reference to two PCT applications, namely WO99/41377 and WO00/78964. These applications describe and contain the nucleic acid and amino acid sequences for a molecule known as " $\alpha 2$ ".
4. I have been informed that sequence information for $\alpha 2$ should be added to U.S. Patent Application Serial No. 09/818,954. This information has been added by way of amendment filed with this declaration.
5. The amendatory material consists of the same material incorporated by reference in the referencing application, U.S. Patent Application Serial No. 09/818,954.

EXPRESS MAIL CERTIFICATE

"Express Mail" label number: EV 351339992 US

Date of Deposit: May 21, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature

I further declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 USC 1001), and may jeopardize the validity of the application or any patent issuing thereon.

Christopher J. R. Paszty
Christopher J. R. Paszty

5/21/2003
Date

Please send all future correspondence to:

US Patent Operations/ SNB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799